• About the Journal
    Exploration of Targeted Anti-tumor Therapy (eISSN 2692-3114), a peer-reviewed, open access online journal, publishes articles on all aspects of cancer research, including clinical diagnosis and analysis, case report, prevention, intervention treatment, pre-clinical and clinical trials of all types of cancers. Submissions with good originality, well-designed experiments and rigorous data are particularly welcomed.
    From the Editors-in-Chief
    It is a particularly exciting time to be involved in cancer research and I am delighted to take on the role of co-Editor-in-Chief of the new journal Exploration of Targeted Anti-tumor Therapy. The journal will provide a platform for publication of studies on all aspects of the development of targeted anti-cancer drugs and will appeal to a broad range of readers. I look forward to receiving submissions of your manuscripts describing cutting-edge research in this fast moving and important field.
    Graham Packham
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    I am really honored to take on the role of co-Editor-in-Chief of this new journal—Exploration of Targeted Anti-tumor Therapy. Like many colleagues, I spent a large part of my professional life researching new cancer therapies. The efforts of the scientific community have allowed the development of targeted therapies to affect significantly the course of the main tumors. In this scenario, ETAT wants to represent a platform for discussion and evaluation on all aspects related to the development of targeted therapies, from the identification of the target to its validation and clinical exploration, including the evaluation of biomarkers of activity and toxicity. We therefore await your contributions to build together a place of confrontation that favors scientific progress in the field of target therapies.
    Nicola Normanno
    Co-Editor-in-Chief of Exploration of Targeted Anti-tumor Therapy
    Latest Articles
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the...
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther 2020;1:183-199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    Viewed:102
    Downloaded:5
    Cited:0
    Open Access
    Review
    Integration of PARP-inhibitors in ovarian cancer therapy
    Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting....
    Antonella Pietragalla ... Gennaro Daniele
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:171-182
    DOI: https://doi.org/10.37349/etat.2020.00011
    Viewed:38
    Downloaded:5
    Cited:0
    Open Access
    Review
    An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
    Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone ...
    Irum Naz ... Kwang Seok Ahn
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153-170
    DOI: https://doi.org/10.37349/etat.2020.00010
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    Viewed:148
    Downloaded:15
    Cited:0
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    Viewed:226
    Downloaded:23
    Cited:0